Abstracts tagged "Clinical practice"

Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Doquyen H. Huynh¹, Carol J. Etzel^2,3, Vanessa Cox⁴, Philip J. Mease⁵ and Arthur Kavanaugh⁶, ¹Rheumatology, UC San Diego School of Medicine, San Diego, CA, ²PO Box 786, Corrona, LLC., Southborough, MA, ³Department of Epidemiology, UT MD Anderson, Houston, TX, ⁴CORRONA, Inc, Southborough, MA, ⁵CORRONA, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…
Abstract Number: 1445 • 2014 ACR/ARHP Annual Meeting
Improving Osteoarthritis Outcomes Utilizing a Multidisciplinary Model of Care; Experience in a Diverse Multicultural Urban Teaching Hospital
Caroline Jones¹, Laurence A. Rubin², Angelo Papachristos³, Elaine Harniman³ and Jann Patrick Ong⁴, ¹Mobility Program, St. Michael's Hospital, Aurora, ON, Canada, ²Rheumatology, St. Michael Hospital, Toronto, ON, Canada, ³Physiotherapy, St Michael's Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose In 2008, a multidisciplinary osteoarthritis (MOA) clinic was established at St. Michael’s Hospital (SMH), a tertiary care academic teaching facility, serving a diverse social,…
Abstract Number: 1163 • 2014 ACR/ARHP Annual Meeting
Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics
Christie M. Bartels¹, Joanna Wong², Heather Johnson³, Katya Voelker⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Tufts University School of Medicine, Boston, MA, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Experts recommend discussing modifiable cardiovascular disease (CVD) risk factors in RA visits. We examined the predictors of discussions about cholesterol and or lifestyle (weight,…
Abstract Number: 942 • 2014 ACR/ARHP Annual Meeting
ACR/EULAR Remission in RA patients in Clinical Practice – Does Substitution of Patient Global with Pain Score Change Remission Rates? Data from the Danish Danbio Registry
Merete Lund Hetland, On behalf of all Depts of Rheumatology in Denmark, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: Modern treatment strategy in RA aims at remission. In 2011, new ACR/EULAR remission criteria were published for patients with RA. Of four Boolean criteria,…
Abstract Number: 906 • 2014 ACR/ARHP Annual Meeting
How Long Does Sonographic Joint Activity Continue in Clinically Remittive Joints of Patients with Rheumatoid Arthritis?
Miriam Gärtner¹, Farideh Alasthi², Gabriela Supp¹, Peter Mandl², Josef Smolen¹ and Daniel Aletaha¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III, Devision of Rheumatology, Medical University of Vienna, Vienna, Austria
How long does sonographic joint activity continue in clinically remittive joints of patients with rheumatoid arthritis? M. Gärtner, F. Alasthi, G. Supp, P. Mandl, JS…
Abstract Number: 2499 • 2014 ACR/ARHP Annual Meeting
Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients
Massimiliano Cazzato¹, Laura Bazzichi², Stefano Bombardieri³ and Camillo Giacomelli⁴, ¹Internal Medicine, Rheumatology Unit, Pisa, Italy, ²Santa Chiara Hospital, Rheumatology, pisa, Italy, ³Rheumatology Unit, Pisa, Italy, ⁴Rheumatology, pisa, Italy
Background/Purpose In the last few years the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 424 • 2014 ACR/ARHP Annual Meeting
The Comparison Between Physical and Ultrasound Joint Examination for the Hand Joints in Patients with Rheumatoid Arthritis
Norihide Hayashi¹, Takehisa Ogura², Ayako Hirata², Rie Kujime³, Munetsugu Imamura¹, Sayaka Takenaka³, Kennosuke Mizushina³, Sumie Nakahashi³, Hideki Ito¹, Naoko Yamashita³ and Hideto Kameda¹, ¹Div Rheumatol, Dep Intern Med, Toho Univ, Tokyo, Japan, ²Department of Rheumatology, Toho Univ, Tokyo, Japan, ³Toho Univ, Tokyo, Japan
Background/Purpose To establish the importance of joint examination by ultrasound (US) in daily clinical practice of patients with rheumatoid arthritis (RA), we compared the US…
Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database
Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA
Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…
Abstract Number: 430 • 2014 ACR/ARHP Annual Meeting
Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Kumi Shidara, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Patient-reported outcomes (PROs) have been recognized as important in evaluating disease status of rheumatoid arthritis (RA). The minimally important difference (MID) in PROs has…
Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort
Ruediger Mueller¹, Johannes von Kempis¹, Michael H Schiff² and Sarah Haile³, ¹Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland, ²University of Colorado, Denver, CO, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…
Abstract Number: 265 • 2014 ACR/ARHP Annual Meeting
Prevalence of Medicinal Marijuana Use Among 1000 Rheumatology Patients Attending a Community-Based Rheumatology Clinic: A Prospective Cross-Sectional Study
Peter A. Ste-Marie¹, Yoram Shir¹, Emmanouil Rampakakis², John S. Sampalis^2,3, Martin Cohen⁴, Michael Starr⁵, Mark A Ware¹ and Mary-Ann Fitzcharles⁶, ¹Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Mcgill University Health Centre, Montreal, QC, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: With a worldwide groundswell of interest in cannabinoids as a possible treatment option for persons with rheumatic diseases, and with few pharmacologic cannabinoid options…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].